drugset / Trial / NCT01388322
Low Weight Heparin prOphylaxis for Placental-Mediated Complications of PrEgnancy
Phase 3
Completed
361 enrolled
Hospital Universitari Vall d'Hebron Research Institute
Hospital Sant Joan de Deu · collabHospital Vall d'Hebron · collabHospital de Cruces · collabParc Sanitari Sant Joan de Déu · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This is a Multicenter, randomized, open-label, parallel groups study to test the hypothesis that prophylactic low molecular weight heparin (LMWH) (enoxaparin) initiated before 14 weeks of gestation could improve maternal and perinatal outcome in women at high risk for developing placental-mediated pregnancy complications.
Timeline
- Start
- 2012-03
- Primary completion
- 2016-06
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enoxaparin sodium | Other / unclassified | 40 mg | Subcutaneous |
| Subject | Enoxaparin sodium | Other / unclassified | 60 mg | Subcutaneous |